{"id":"insulin-dapaglifozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Diabetic ketoacidosis"},{"rate":null,"effect":"Volume depletion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination therapy where insulin acts as an exogenous hormone to facilitate cellular glucose uptake and utilization, while dapagliflozin, an SGLT2 inhibitor, works independently by blocking sodium-glucose cotransporter 2 in the proximal tubule, causing urinary glucose excretion. The combination targets hyperglycemia through complementary mechanisms: insulin addresses intracellular glucose metabolism and dapagliflozin enhances renal glucose clearance.","oneSentence":"Insulin provides glucose control via glucose uptake and metabolism, while dapagliflozin lowers blood glucose by inhibiting renal glucose reabsorption through SGLT2 blockade.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:17.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus in patients requiring insulin therapy"}]},"trialDetails":[{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT02325206","phase":"PHASE1","title":"Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2014-12","conditions":"Type 1 Diabetes","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin/Dapaglifozin","genericName":"Insulin/Dapaglifozin","companyName":"University of Campania Luigi Vanvitelli","companyId":"university-of-campania-luigi-vanvitelli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin provides glucose control via glucose uptake and metabolism, while dapagliflozin lowers blood glucose by inhibiting renal glucose reabsorption through SGLT2 blockade. Used for Type 2 diabetes mellitus in patients requiring insulin therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}